DADC
JAZZ icon

D.A. Davidson & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

D.A. Davidson & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$15K – 1557
2017
Q2 		$15K Hold
100
– – ﹤0.01% 1902
2017
Q1 		$14K Hold
100
– – ﹤0.01% 1925
2016
Q4 		$10K Buy
+100
New +$11.1K ﹤0.01% 2115
2015
Q3 		– Sell
-435
Closed -$76K – 2233
2015
Q2 		$76K Hold
435
– – ﹤0.01% 1268
2015
Q1 		$75K Hold
435
– – ﹤0.01% 1258
2014
Q4 		$71K Buy
+435
New +$72.2K ﹤0.01% 1290
2014
Q2 		– Sell
-150
Closed -$20K – 2129
2014
Q1 		$20K Hold
150
– – ﹤0.01% 1643
2013
Q4 		$18K Buy
+150
New +$15.5K ﹤0.01% 1581

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
SIG
Senator Investment Group New York $2.74B AUM 55.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

D.A. Davidson & Co's JAZZ Position: Q3 2017 in Review

D.A. Davidson & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 100 shares — an estimated $15K sold.

D.A. Davidson & Co first reported a position in JAZZ in Q4 2013 and held it in 8 quarters. The position peaked at $76K in Q2 2015. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • D.A. Davidson & Co reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 100 Jazz Pharmaceuticals shares in Q3 2017, an estimated $15K.
  • D.A. Davidson & Co first reported a position in Jazz Pharmaceuticals in Q4 2013 and held it in 8 quarters.
  • D.A. Davidson & Co's Jazz Pharmaceuticals position peaked at $76K in Q2 2015.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.